This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Friday, October 27, 2017
News Recap:
Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6. We need to hear your voice by November 8, 2017! AbbVie’s “GP” combo is pan-genotypic (works for all genotypes).
Liver Meeting 2017: I’m A HCV Patient – Show Me What I Need to Know! Why reinvent the wheel? The good folks over at HCV New Drugs have put together this great overview of what happened at the AASLD Conference (2017) using easy to follow video clips, and future learning activities.
DAA Era Linked with Better Liver Transplant Outcomes. Patients with chronic hepatitis C have done better after liver transplant in the era of direct-acting agents (DAAs) against the virus. In a retrospective analysis of transplant outcomes, the DAA era was associated with a 36% drop in mortality a year after transplant.
HBV
Transgene‘s Hepatitis B Vaccine Does the Business at Phase I. The French biotech‘s hepatitis B vaccine TG1050 has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus.
There was other news with regard to HBV as well. A study from Taiwan showed that daily dose of low-level aspirin was associated with a lower incidence of HCC (https://goo.gl/epKkvK), but please don’t just go and start taking low-dose aspirin – especially if you have clotting problems or are on blood-thinners for your heart!
There was also a report on another HBV drug in development, NASVAC, from Bangladesh (https://goo.gl/29xPB7). However, don’t be misled by everything you read. NASVAC – also known as ABX203 or ABIVAX – has been the subject of many clinical trials over the last few years that have shown that the drug shows good safety, but that it isn’t very effective.